Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following ...